NasdaqCM:AKBA
NasdaqCM:AKBABiotechs

Why Akebia Therapeutics (AKBA) Is Up After Strong Q3 Earnings and Promising Vafseo Kidney Data

In the past week, Akebia Therapeutics reported third-quarter 2025 earnings, showing total revenue rising to US$58.77 million from US$37.43 million a year earlier and a net income swing to US$0.54 million compared to a net loss previously. This robust financial turnaround was accompanied by new clinical data presented at ASN Kidney Week 2025, indicating Vafseo may offer dialysis patients a significantly reduced risk of death or hospitalization versus standard therapy. We’ll explore how this...
NYSE:EQH
NYSE:EQHDiversified Financial

Equitable Holdings (NYSE:EQH): Assessing Valuation After Q3 Losses and Stifel Acquisition News

Equitable Holdings (NYSE:EQH) has been in the spotlight after reporting third-quarter results that reflected losses from a life reinsurance transaction and higher mortality costs. The company also announced the strategic acquisition of Stifel Independent Advisors. See our latest analysis for Equitable Holdings. Shares of Equitable Holdings have come under pressure following third-quarter results that reflected both one-off charges and ongoing challenges. The company remains focused on...